Antisense Oligonucleotide

Avacincaptad pegol 2 mg intravitreal injection for Age-Related Macular Degeneration

Phase 3
Waitlist Available
Research Sponsored by IVERIC bio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Upmonth 18
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Study Summary

This trial will test a new medication for patients with myelofibrosis. The medication will be given monthly, and the trial will monitor the effects.

Eligible Conditions
  • Age-Related Macular Degeneration


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 18
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 18 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Avacincaptad pegol 2 mgExperimental Treatment1 Intervention
Avacincaptad pegol 2 mg administered monthly from Month 1 to Month 17

Find a site

Who is running the clinical trial?

IVERIC bio, Inc.Lead Sponsor
4 Previous Clinical Trials
855 Total Patients Enrolled
Medical DirectorStudy Chair
IVERIC bio, Inc.
2,710 Previous Clinical Trials
7,992,003 Total Patients Enrolled

Media Library

Avacincaptad Pegol (Antisense Oligonucleotide) Clinical Trial Eligibility Overview. Trial Name: NCT05536297 — Phase 3
Age-Related Macular Degeneration Research Study Groups: Avacincaptad pegol 2 mg
Age-Related Macular Degeneration Clinical Trial 2023: Avacincaptad Pegol Highlights & Side Effects. Trial Name: NCT05536297 — Phase 3
Avacincaptad Pegol (Antisense Oligonucleotide) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05536297 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we still recruiting new participants for this research?

"Sadly, this particular clinical trial is not currently looking for patients. Although the trial's most recent update was on September 26th, 2022, the study is not currently recruiting. However, there are 329 other trials that are currently looking for patients."

Answered by AI

Has the FDA cleared Avacincaptad pegol 2 mg intravitreal injection for use?

"Avacincaptad pegol 2 mg intravitreal injection receives a safety score of 3 from our Power team. This is due to it being a Phase 3 trial, meaning that, while there is some efficacy data, there is more supporting data for its safety."

Answered by AI
~207 spots leftby Jan 2025